Amlodipine And Valsartan (Amlodipine And Valsartan)

Trade Name : AMLODIPINE AND VALSARTAN

Mylan Pharmaceuticals Inc.

TABLET, FILM COATED

Strength 5160 mg/1mg/1

AMLODIPINE BESYLATE; VALSARTAN Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [CS],Angiotensin 2 Receptor Antagonists [MoA],Angiotensin 2 Receptor Blocker [EPC]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Amlodipine And Valsartan (Amlodipine And Valsartan) which is also known as AMLODIPINE AND VALSARTAN and Manufactured by Mylan Pharmaceuticals Inc.. It is available in strength of 5; 160 mg/1; mg/1 per ml. Read more

Amlodipine And Valsartan (Amlodipine And Valsartan) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • WARNING: FETAL TOXICITY
  • See full prescribing information for complete boxed warning.
  • When pregnancy is detected, discontinue amlodipine and valsartan tablets as soon as possible. ()
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ()
  • Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine and valsartan tablets.
  • Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Programu2019s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
  • Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
  • Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
  • Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine and valsartan tablets are indicated for the treatment of hypertension.
  • Amlodipine and valsartan tablets may be used in patients whose blood pressure is not adequately controlled on either monotherapy.
  • Amlodipine and valsartan tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
  • The choice of amlodipine and valsartan tablets as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the lowest dose of amlodipine and valsartan tablets.
  • Patients with stage 2 hypertension (moderate or severe) are at a relatively higher risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patientu2019s risk.
  • Data from the high-dose multifactorial study provide estimates of the probability of reaching a blood pressure goal with amlodipine and valsartan tablets compared to amlodipine or valsartan monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with amlodipine and valsartan tablets 10/320 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures.
  • For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 67% likelihood of achieving a goal of < 140 mmHg (systolic) and 80% likelihood of achieving < 90 mmHg (diastolic) on amlodipine alone, and the likelihood of achieving these goals on valsartan alone is about 47% (systolic) or 62% (diastolic). The likelihood of achieving these goals on amlodipine and valsartan tablets rises to about 80% (systolic) or 85% (diastolic). The likelihood of achieving these goals on placebo is about 28% (systolic) or 37% (diastolic).
  • Amlodipine and valsartan is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure:
  • Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
  • General Considerations:
  • Hypertension:
  • Amlodipine and Valsartan Tablets, USP are available containing 6.94 mg or 13.88 mg of amlodipine besylate, USP equivalent to 5 mg or 10 mg of amlodipine free base, respectively, with 160 mg or 320 mg of valsartan, USP providing for the following available combinations: 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg or 10 mg/320 mg.
  • Tablets (amlodipine/valsartan mg): 5/160, 10/160, 5/320, 10/320 ()
  • Do not use in patients with known hypersensitivity to any component.
  • Do not coadminister aliskiren with amlodipine and valsartan tablets in patients with diabetes .
  • Known hypersensitivity to any component;
  • Do not coadminister aliskiren with amlodipine and valsartan tablets in patients with diabetes ()
  • No data
  • 5.4n- 5.5
  • In placebo-controlled clinical trials, discontinuation due to side effects occurred in 1.8% of patients in the amlodipine and valsartan tablet-treated patients and 2.1% in the placebo-treated group. The most common reasons for discontinuation of therapy with amlodipine and valsartan tablets were peripheral edema and vertigo. The adverse experiences that occurred in clinical trials (u2265 2% of patients) at a higher incidence than placebo included peripheral edema, nasopharyngitis, upper respiratory tract infection, and dizziness. ()
  • To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • No drug interaction studies have been conducted with amlodipine and valsartan tablets and other drugs, although studies have been conducted with the individual amlodipine and valsartan components.
  • Amlodipine: n n- CYP3A Inhibitors:n- [see ]
  • CYP3A Inducers:
  • Sildenafil:n- [see ]
  • Arrayn- [see ]
  • Immunosuppressants: n- [see ]
  • Valsartan:n- Array
  • Arrayn- Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors):
  • The antihypertensive effect of angiotensin II receptor antagonists, including valsartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.
  • Arrayn- Dual Blockade of the Renin-Angiotensin System (RAS):
  • Do not coadminister aliskiren with amlodipine and valsartan in patients with diabetes. Avoid use of aliskiren with amlodipine and valsartan in patients with renal impairment (GFR < 60 mL/min).
  • Arrayn- Lithium:
  • Lactation:
  • Amlodipine:
  • Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension. In humans, experience with intentional overdosage of amlodipine is limited. Marked and potentially prolonged systemic hypotension up to and including shock with fatal outcome have been reported.
  • If massive overdose should occur, initiate active cardiac and respiratory monitoring. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. If hypotension remains unresponsive to these conservative measures, consider administration of vasopressors (such as phenylephrine) with attention to circulating volume and urine output. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit. Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine has been shown to significantly decrease amlodipine absorption.
  • Valsartan:
  • Valsartan is not removed from the plasma by hemodialysis.
  • Valsartan was without grossly observable adverse effects at single oral doses up to 2000 mg/kg in rats and up to 1000 mg/kg in marmosets, except for the salivation and diarrhea in the rat and vomiting in the marmoset at the highest dose (60 and 37 times, respectively, the MRHD on a mg/m basis). (Calculations assume an oral dose of 320 mg/day and a 60 kg patient.)
  • Amlodipine and valsartan tablets, USP are a fixed combination of amlodipine and valsartan.
  • Amlodipine and valsartan tablets contain the besylate salt of amlodipine, a dihydropyridine calcium-channel blocker (CCB). Amlodipine besylate, USP is a white or almost white powder, slightly soluble in water and sparingly soluble in ethanol. Amlodipine besylateu2019s chemical name is 3-ethyl-5-methyl (4)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulfonate; its structural formula is:
  • Its molecular formula is CHClNOu2022CHOS and its molecular weight is 567.1.
  • Valsartan is a nonpeptide, orally active, and specific angiotensin II antagonist acting on the AT receptor subtype. Valsartan, USP is a white to almost white amorphous powder, soluble in ethanol and methanol and slightly soluble in water. Valsartanu2019s chemical name is -[-(-1-Tetrazol-5-ylphenyl)benzyl]--valeryl--valine; its structural formula is:
  • Its molecular formula is CHNO and its molecular weight is 435.52.
  • Amlodipine and valsartan tablets are formulated in 4 strengths for oral administration with a combination of amlodipine besylate, equivalent to 5 mg or 10 mg of amlodipine free base, with 160 mg, or 320 mg of valsartan providing for the following available combinations: 5/160 mg, 10/160 mg, 5/320 mg, and 10/320 mg.
  • The inactive ingredients for all strengths of the tablets are colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, red iron oxide, sodium starch glycolate (potato), talc, titanium dioxide and yellow iron oxide.
  • Meets USP Dissolution Test 3.
  • No data
  • No data
  • Amlodipine and valsartan tablets were studied in 2 placebo-controlled and 4 active-controlled trials in hypertensive patients. In a double-blind, placebo-controlled study, a total of 1012 patients with mild-to-moderate hypertension received treatments of 3 combinations of amlodipine and valsartan (5/80, 5/160, 5/320 mg) or amlodipine alone (5 mg), valsartan alone (80, 160, or 320 mg) or placebo. All doses with the exception of the 5/320 mg dose were initiated at the randomized dose. The high dose was titrated to that dose after a week at a dose of 5/160 mg. At week 8, the combination treatments were statistically significantly superior to their monotherapy components in reduction of diastolic and systolic blood pressures.
  • In a double-blind, placebo-controlled study, a total of 1246 patients with mild-to-moderate hypertension received treatments of 2 combinations of amlodipine and valsartan (10/160, 10/320 mg), or amlodipine alone (10 mg), valsartan alone (160 or 320 mg) or placebo. With the exception of the 10/320 mg dose, treatment was initiated at the randomized dose. The high dose was initiated at a dose of 5/160 mg and titrated to the randomized dose after 1 week. At week 8, the combination treatments were statistically significantly superior to their monotherapy components in reduction of diastolic and systolic blood pressures.
  • In a double-blind, active-controlled study, a total of 947 patients with mild-to-moderate hypertension who were not adequately controlled on valsartan 160 mg received treatments of 2 combinations of amlodipine and valsartan (10/160, 5/160 mg) or valsartan alone (160 mg). At week 8, the combination treatments were statistically significantly superior to the monotherapy component in reduction of diastolic and systolic blood pressures.
  • In a double-blind, active-controlled study, a total of 944 patients with mild-to-moderate hypertension who were not adequately controlled on amlodipine 10 mg received a combination of amlodipine and valsartan (10/160 mg) or amlodipine alone (10 mg). At week 8, the combination treatment was statistically significantly superior to the monotherapy component in reduction of diastolic and systolic blood pressures.
  • Amlodipine and valsartan tablets were also evaluated for safety in a 6-week, double-blind, active-controlled trial of 130 hypertensive patients with severe hypertension (mean baseline BP of 171/113 mmHg). Adverse events were similar in patients with severe hypertension and mild/moderate hypertension treated with amlodipine and valsartan tablets.
  • A wide age range of the adult population, including the elderly was studied (range 19 to 92 years, mean 54.7 years). Women comprised almost half of the studied population (47.3%). Of the patients in the studied amlodipine and valsartan tablets group, 87.6% were Caucasian. Black and Asian patients each represented approximately 4% of the population in the studied amlodipine and valsartan tablets group.
  • Two additional double-blind, active-controlled studies were conducted in which amlodipine and valsartan tablets were administered as initial therapy. In 1 study, a total of 572 black patients with moderate to severe hypertension were randomized to receive either combination amlodipine/valsartan or amlodipine monotherapy for 12 weeks. The initial dose of amlodipine/valsartan was 5/160 mg for 2 weeks with forced titration to 10/160 mg for 2 weeks, followed by optional titration to 10/320 mg for 4 weeks and optional addition of HCTZ 12.5 mg for 4 weeks. The initial dose of amlodipine was 5 mg for 2 weeks with forced titration to 10 mg for 2 weeks, followed by optional titration to 10 mg for 4 weeks and optional addition of HCTZ 12.5 mg for 4 weeks. At the primary endpoint of 8 weeks, the treatment difference between amlodipine/valsartan and amlodipine was 6.7/2.8 mmHg.
  • In the other study of similar design, a total of 646 patients with moderate to severe hypertension (MSSBP of u2265 160 mmHg and < 200 mmHg) were randomized to receive either combination amlodipine/valsartan or amlodipine monotherapy for 8 weeks. The initial dose of amlodipine/valsartan was 5/160 mg for 2 weeks with forced titration to 10/160 mg for 2 weeks, followed by the optional addition of HCTZ 12.5 mg for 4 weeks. The initial dose of amlodipine was 5 mg for 2 weeks with forced titration to 10 mg for 2 weeks, followed by the optional addition of HCTZ 12.5 mg for 4 weeks. At the primary endpoint of 4 weeks, the treatment difference between amlodipine/valsartan and amlodipine was 6.6/3.9 mmHg.
  • There are no trials of the amlodipine and valsartan combination tablet demonstrating reductions in cardiovascular risk in patients with hypertension, but the amlodipine component and several ARBs, which are the same pharmacological class as the valsartan component, have demonstrated such benefits.
  • Amlodipine and Valsartan Tablets, USP are available containing 6.94 mg or 13.88 mg of amlodipine besylate, USP equivalent to 5 mg or 10 mg of amlodipine free base, respectively, with 160 mg or 320 mg of valsartan, USP providing for the following available combinations: 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg or 10 mg/320 mg.
  • The 5 mg/160 mg tablets are light orange, film-coated, oval, unscored tablets debossed with on one side of the tablet and blank on the other side. They are available as follows:
  • NDC 0378-1721-93bottles of 30 tablets
  • The 10 mg/160 mg tablets are tan, film-coated, oval, unscored tablets debossed with on one side of the tablet and blank on the other side. They are available as follows:
  • NDC 0378-1722-93bottles of 30 tablets
  • The 5 mg/320 mg tablets are orange, film-coated, capsule-shaped, unscored tablets debossed with on one side of the tablet and blank on the other side. They are available as follows:
  • NDC 0378-1723-93bottles of 30 tablets
  • The 10 mg/320 mg tablets are light orange, film-coated, capsule-shaped, unscored tablets debossed with on one side of the tablet and blank on the other side. They are available as follows:
  • NDC 0378-1724-93bottles of 30 tablets
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F). [See USP Controlled Room Temperature.]
  • Protect from moisture.
  • Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
  • Information for Patients:
  • Arrayn- [see and ]
  • Arrayn- [see ]
  • Arrayn- [see ]
  • Arrayn- [see ]
  • FDA-APPROVED PATIENT LABELING
  • Amlodipine and Valsartan Tablets, USPn- (am loeu2032 di peen val saru2032 tan)
  • Read the Patient Information that comes with amlodipine and valsartan tablets before you start taking them and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment. If you have any questions about amlodipine and valsartan tablets, ask your doctor or pharmacist.
  • What are amlodipine and valsartan tablets?
  • Amlodipine and valsartan tablets contain 2 prescription medicines:
  • Amlodipine and valsartan tablets may be used to lower high blood pressure (hypertension) in adults
  • Amlodipine and valsartan tablets have not been studied in children under 18 years of age.
  • What should I tell my doctor before taking amlodipine and valsartan tablets?
  • Tell your doctor about all of your medical conditions, including if you:
  • Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Some of your other medicines and amlodipine and valsartan tablets could affect each other, causing serious side effects.
  • Especially tell your doctor if you take:
  • Know the medicines you take. Keep a list of your medicines and show it to your doctor or pharmacist when you get a new medicine. Talk to your doctor or pharmacist before you start taking any new medicine. Your doctor or pharmacist will know what medicines are safe to take together.
  • How should I take amlodipine and valsartan tablets?
  • What should I avoid while taking amlodipine and valsartan tablets?
  • You should not take amlodipine and valsartan tablets during pregnancy. See n
  • What are the possible side effects of amlodipine and valsartan tablets?
  • Amlodipine and valsartan tablets may cause including:
  • The most common side effects of amlodipine and valsartan tablets include:
  • Tell your doctor if you have any side effect that bothers you or that does not go away.
  • These are not all the possible side effects of amlodipine and valsartan tablets. For more information, ask your doctor or pharmacist.
  • Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
  • How should I store amlodipine and valsartan tablets?
  • Keep amlodipine and valsartan tablets and all medicines out of the reach of children.
  • General information about amlodipine and valsartan tablets
  • Medicines are sometimes prescribed for conditions that are not mentioned in the patient information leaflet. Do not use amlodipine and valsartan tablets for a condition for which they were not prescribed. Do not give amlodipine and valsartan tablets to other people, even if they have the same symptoms that you have. They may harm them.
  • This patient information leaflet summarizes the most important information about amlodipine and valsartan tablets. If you would like more information about amlodipine and valsartan tablets, talk with your doctor. You can ask your doctor or pharmacist for information about amlodipine and valsartan tablets that is written for health professionals. For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX).
  • What are the ingredients in amlodipine and valsartan tablets?
  • Active ingredients: amlodipine besylate and valsartan
  • The inactive ingredients of all strengths of the tablets are colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, red iron oxide, sodium starch glycolate (potato), talc, titanium dioxide and yellow iron oxide.
  • What is high blood pressure (hypertension)?
  • Blood pressure is the force of blood in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. Amlodipine and valsartan tablets can help your blood vessels relax so your blood pressure is lower. Medicines that lower blood pressure lower your chance of having a stroke or heart attack.
  • High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to blood vessels. If high blood pressure is not treated, it can lead to stroke, heart attack, heart failure, kidney failure, and vision problems.
  • The brands listed are trademarks of their respective owners.
  • Manufactured for:n n Morgantown, WV 26505 U.S.A.
  • Manufactured by:n n Hyderabad u2014 500 096, Indian
  • 75068926
  • Revised: 7/2019MX:AMLOVALT:R4
  • NDC 0378-1721-93
  • Amlodipine and n- Valsartann- Tablets, USPn- 5 mg/n- 160 mg
  • Rx onlyu00a0u00a0u00a0u00a030 Tablets
  • Each film-coated tablet contains:Amlodipine besylate, USP 6.94 mg(equivalent to Amlodipine) 5 mgValsartan, USP 160 mg
  • Usual Dosage:
  • Keep this and all medication out of then- reach of children.
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F). [Seen- USP Controlled Room Temperature.]
  • Protect from moisture.
  • Manufactured for:n n Morgantown, WV 26505 U.S.A.
  • Made in India
  • Mylan.com
  • RMX1721H2
  • Dispense in a tight, light-resistantcontainer as defined in the USPusing a child-resistant closure.
  • Keep container tightly closed.
  • Code No.: MH/DRUGS/25/NKD/89
  • NDC 0378-1722-93
  • Amlodipine andn- Valsartann- Tablets, USPn- 10 mg/n- 160 mg
  • Rx onlyu00a0u00a0u00a0u00a030 Tablets
  • Each film-coated tablet contains:Amlodipine besylate, USP 13.88 mg(equivalent to Amlodipine) 10 mgValsartan, USP 160 mg
  • Usual Dosage:
  • Keep this and all medication out of then- reach of children.
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F). [Seen- USP Controlled Room Temperature.]
  • Protect from moisture.
  • Manufactured for:n n Morgantown, WV 26505 U.S.A.
  • Made in India
  • Mylan.com
  • RMX1722H2
  • Dispense in a tight, light-resistantcontainer as defined in the USPusing a child-resistant closure.
  • Keep container tightly closed.
  • Code No.: MH/DRUGS/25/NKD/89
  • NDC 0378-1723-93
  • Amlodipine andn- Valsartann- Tablets, USPn- 5 mg/n- 320 mg
  • Rx onlyu00a0u00a0u00a0u00a030 Tablets
  • Each film-coated tablet contains:Amlodipine besylate, USP 6.94 mg(equivalent to Amlodipine) 5 mgValsartan, USP 320 mg
  • Usual Dosage:
  • Keep this and all medication out of then- reach of children.
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F). [Seen- USP Controlled Room Temperature.]
  • Protect from moisture.
  • Manufactured for:n n Morgantown, WV 26505 U.S.A.
  • Made in India
  • Mylan.com
  • RMX1723H2
  • Dispense in a tight, light-resistantcontainer as defined in the USPusing a child-resistant closure.
  • Keep container tightly closed.
  • Code No.: MH/DRUGS/25/NKD/89
  • NDC 0378-1724-93
  • Amlodipine andn- Valsartann- Tablets, USPn- 10 mg/n- 320 mg
  • Rx onlyu00a0u00a0u00a0u00a030 Tablets
  • Each film-coated tablet contains:Amlodipine besylate, USP 13.88 mg(equivalent to Amlodipine) 10 mgValsartan, USP 320 mg
  • Usual Dosage:
  • Keep this and all medication out of then- reach of children.
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F). [Seen- USP Controlled Room Temperature.]
  • Protect from moisture.
  • Manufactured for:n n Morgantown, WV 26505 U.S.A.
  • Made in India
  • Mylan.com
  • RMX1724H2
  • Dispense in a tight, light-resistantcontainer as defined in the USPusing a child-resistant closure.
  • Keep container tightly closed.
  • Code No.: MH/DRUGS/25/NKD/89

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Dossiers and Stability Studies

Dossiers and Stability Studies

STABILITY STUDIES STABILITY, BA / BE STUDIES Due to our active

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71247 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.